Pages that link to "Q40255904"

The following pages link to Newly identified c-KIT receptor tyrosine kinase ITD in childhood AML induces ligand-independent growth and is responsive to a synergistic effect of imatinib and rapamycin (Q40255904):

Displaying 28 items.

• Mechanism of activation of human c-KIT kinase by internal tandem duplications of the juxtamembrane domain and point mutations at aspartic acid 816 (Q24305445) (← links)
• ITD assembler: an algorithm for internal tandem duplication discovery from short-read sequencing data (Q31086279) (← links)
• A point mutation in the extracellular domain of KIT promotes tumorigenesis of mast cells via ligand-independent auto-dimerization (Q35596167) (← links)
• High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia (Q36591388) (← links)
• Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms (Q36798620) (← links)
• Stat5 as a diagnostic marker for leukemia (Q37035281) (← links)
• Cooperating gene mutations in acute myeloid leukemia: a review of the literature. (Q37089717) (← links)
• Pediatric developmental therapies: interesting new drugs now in early-stage clinical trials (Q37301320) (← links)
• Clinical implications of c-Kit mutations in acute myelogenous leukemia. (Q37738571) (← links)
• Tetraspanins Function as Regulators of Cellular Signaling. (Q37739091) (← links)
• Activated leukemic oncogenes AML1-ETO and c-kit: Role in development of acute myeloid leukemia and current approaches for their inhibition (Q37854763) (← links)
• STAT5-mediated self-renewal of normal hematopoietic and leukemic stem cells (Q38140877) (← links)
• Retrograde TrkAIII transport from ERGIC to ER: a re-localisation mechanism for oncogenic activity. (Q38262750) (← links)
• RIST: a potent new combination therapy for glioblastoma (Q38966022) (← links)
• FLT3-ITD and its current role in acute myeloid leukaemia (Q39282600) (← links)
• Reactivating PP2A by FTY720 as a novel therapy for AML with C-KIT tyrosine kinase domain mutation (Q39438493) (← links)
• Evaluation of tyrosine-kinase receptor c-KIT (c-KIT) mutations, mRNA and protein expression in canine leukemia: might c-KIT represent a therapeutic target? (Q39473798) (← links)
• The PI3K/Akt/mTOR pathway mediates retinal progenitor cell survival under hypoxic and superoxide stress (Q39564780) (← links)
• Aberrant autophosphorylation of c-Kit receptor in canine mast cell tumor cell lines (Q39686603) (← links)
• Effective targeting of STAT5-mediated survival in myeloproliferative neoplasms using ABT-737 combined with rapamycin (Q39695105) (← links)
• Activation of Wnt signaling in cKit-ITD mediated transformation and imatinib sensitivity in acute myeloid leukemia (Q39955606) (← links)
• Evolution from heterozygous to homozygous KIT mutation in gastrointestinal stromal tumor correlates with the mechanism of mitotic nondisjunction and significant tumor progression. (Q42542809) (← links)
• KIT and FLT3 receptor tyrosine kinase mutations in acute myeloid leukemia with favorable cytogenetics: two novel mutations and selective occurrence in leukemia subtypes and age groups (Q44448632) (← links)
• The identification and characterisation of novel KIT transcripts in aggressive mast cell malignancies and normal CD34 cells (Q46394282) (← links)
• Monitoring of minimal residual disease in patients with core binding factor acute myeloid leukemia and the impact of C-KIT, FLT3, and JAK2 mutations on clinical outcome. (Q54732689) (← links)
• N822 mutation of KIT gene was frequent in pediatric acute myeloid leukemia patients with t(8;21) in Japan: a study of the Japanese childhood AML cooperative study group (Q80382734) (← links)
• Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11 (Q92402162) (← links)
• A nonrandom association between gastrointestinal stromal tumors and myeloid leukemia (Q94608451) (← links)